Investment Analysts’ Weekly Ratings Updates for InflaRx (IFRX)

A number of research firms have changed their ratings and price targets for InflaRx (NASDAQ: IFRX):

• 5/13/2026 – InflaRx was upgraded by Raymond James Financial, Inc. from “outperform” to “strong-buy”. They now have a $9.00 price target on the stock, up from $7.00.
• 5/11/2026 – InflaRx had its price target raised by HC Wainwright from $6.00 to $8.00. They now have a “buy” rating on the stock.
• 5/11/2026 – InflaRx had its price target raised by Cantor Fitzgerald from $2.00 to $4.00. They now have an “overweight” rating on the stock.
• 5/9/2026 – InflaRx was upgraded by Wall Street Zen from “sell” to “hold”.
• 4/24/2026 – InflaRx is now covered by Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $5.00 price target on the stock.
• 4/21/2026 – InflaRx had its “buy” rating reaffirmed by Guggenheim. They now have a $14.00 price target on the stock.

InflaRx N.V. is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement?1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX?1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro?inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high?unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.